A pragmatic approach to biochemical systems theory applied to an α-synuclein-based model of Parkinson's disease

Journal of Neuroscience Methods

Volumn 178, Issue 2, 2009, Pages 366-377

  Sass, Matthew B ^a   Lorenz, Alyson N ^a   Green, Robert L ^b   Coleman, Randolph A ^a  

^a The College of William and Mary   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Synuclein aggregation; Biochemical systems theory; Dopamine metabolism; Metabolic modeling; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROTOXIN; PROTEASOME; UBIQUITIN;

ARTICLE; AUTOOXIDATION; DOPAMINE METABOLISM; MATHEMATICAL ANALYSIS; MOLECULAR INTERACTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SIMULATION; THEORETICAL MODEL;

ALPHA-SYNUCLEIN; AMYLOID; ANTIPARKINSON AGENTS; COMPUTER SIMULATION; DOPAMINE; GENE EXPRESSION; HUMANS; LEVODOPA; LEWY BODIES; LYSOSOMES; MODELS, NEUROLOGICAL; MONOAMINE OXIDASE INHIBITORS; NEUROTOXINS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; SYSTEMS THEORY; UBIQUITIN;

EID: 61349165474     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2008.12.014     Document Type: Article

References (92)

1. Bandhyopadhyay U., and Cuervo A.M. Chaperone-mediated autophagy in aging and neurodegeneration: lessons from α-synuclein. Exp Gerontol 42 (2007) 120-128
2. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
3. Bennett E.J., Bence N.F., Jayakumar R., and Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17 (2005) 351-365
4. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., and Monks T.J. Role of quinones in toxicology. Chem Res Toxicol 13 (2000) 135-160
5. Bossy-Wetzel E., Schwarzenbacher R., and Lipton S.A. Molecular pathways to neurodegeneration. Nat Med 10 (2004) S2-9
6. Chau V., Tobias J.W., Bachmair A., Marriott D., Ecker D.J., Gonda D.K., et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243 (1989) 1576-1583
7. Choi P., Golts N., Snyder H., Chong M., Petrucelli L., Hardy J., et al. Co-association of parkin and α-synuclein. Neuroreport 12 (2001) 2839-2843
8. Chung K.K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., et al. Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7 (2001) 1144-1150
9. Ciechanover A., and Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40 (2003) 427-446
10. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294 (2001) 1346-1349
11. Cookson M.R. The biochemistry of Parkinson's disease. Annu Rev Biochem 74 (2005) 29-52
12. Cookson M.R., and van der Brug M. Cell systems and the toxic mechanism(s) of α-synuclein. Exp Neurol 209 (2008) 5-11
13. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., and Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 305 (2004) 1292-1295
14. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
15. Dev K.K., Hofele K., Barbieri S., Buchman V.L., and van der Putten H. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45 (2003) 14-44
16. Dev K.K., van der Putten H., Sommer B., and Rovelli G. Part I: parkin-associated proteins and Parkinson's disease. Neuropharmacology 45 (2003) 1-13
17. Ding Q., Dimayuga E., Martin S., Bruce-Keller A., Nukala V., Cuervo A.M., et al. Characterization of chronic low-level proteasome inhibition on neural homeostasis. J Neurochem 86 (2003) 489-497
18. Doss-Pepe E.W., Chen L., and Madura K. Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine63-linked multiubiquitin chains. J Biol Chem 280 (2005) 16619-16624
19. Eisenhofer G., Kopin I.J., and Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56 (2004) 331-349
20. Fasano M., Bergamasco B., and Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96 (2006) 909-916
21. Feany M.B., and Pallanck L.J. Parkin: a multipurpose neuroprotective agent?. Neuron 38 (2003) 13-16
22. Fedorow H., Tribl F., Halliday G., Gerlach M., Riederer P., and Double K.L. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 75 (2005) 109-124
23. Fell D.A. Metabolic control analysis: a survey of its theoretical and experimental development. Biochem J 286 (1992) 313-330
24. Gai W.P., Blessing W.W., and Blumbergs P.C. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 118 (1995) 1447-1459
25. Gerlach M., Riederer P., and Double K.L. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 14 (2008) S185-S188
26. Giasson B.I., Duda J.E., Murray I.V.J., Chen Q., Souza J.M., Hurtig H.L., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
27. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82 (2002) 373-428
28. Gray D.A. Damage control-a possible non-proteolytic role for ubiquitin in limiting neurodegeneration. Neuropathol Appl Neurobiol 27 (2001) 89-94
29. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J Neurochem 97 (2006) 1634-1658
30. Hershko A., and Ciechanover A. The ubiquitin-proteasome pathway. Annu Rev Biochem 67 (1998) 425-479
31. Hicke L. Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. FASEB J 11 (1997) 1215-1226
32. Hicke L. Ubiquitin and proteasomes: protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2 (2001) 195-201
33. Hoops S., Sahle S., Gauges R., Lee C., Pahle J., Simus N., et al. COPASI-a complex pathway simulator. Bioinformatics 22 (2006) 3067-3074
34. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., et al. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157 (2000) 401-410
35. Imai Y., Soda M., and Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275 (2000) 35661-35664
36. Ischiropoulos H., and Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J Clin Invest 111 (2003) 163-169
37. Ito S. A chemist's view of melanogenesis. Pigment Cell Res 16 (2003) 230-236
38. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 S3 (1996) S161-S170
39. Junn E., and Mouradian M.M. Human α-synuclein overexpression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 320 (2002) 146-150
40. Katzmann D.J., Odorizzi G., and Emr S.D. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 3 (2002) 893-905
41. Kaushik P., Gorin F., and Vali S. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comput Neurosci 22 (2007) 147-160
42. Keller J.N., Huang F.F., Dimayuga E.R., and Maragos W.F. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radical Biol Med 29 (2000) 1037-1042
43. Kiffin R., Bandyopadhyay U., and Cuervo A.M. Oxidative stress and autophagy. Antioxid Redox Signal 8 (2006) 152-162
44. Ko L., Mehta N.D., Farrer M., Easson C., Hussey J., Yen S., et al. Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein. J Neurochem 75 (2000) 2546-2554
45. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11 (2005) 1214-1221
46. Lee M., Hyun D., Halliwell B., and Jenner P. Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult. J Neurochem 76 (2001) 998-1009
47. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. PNAS 99 (2002) 8968-8973
48. Lim K., Chew K.C.M., Tan J.M.M., Wang C., Chung K.K.K., Zhang Y., et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25 (2005) 2002-2009
49. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., et al. Proteasomal inhibition by alpha synuclein filaments and oligomers. J Biol Chem 279 (2004) 12924-12934
50. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury Jr. P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
51. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles, and alpha-synuclein. Nat Rev Neurosci 3 (2002) 1-11
52. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. J Biol Chem 275 (2000) 38581-38588
53. Majeski A., and Dice J. Mechanisms of chaperone-mediated autophagy. Int J Biochem Cell Biol 36 (2004) 2435-2444
54. McNaught K.S., Bjorkland L.M., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13 (2002) 1437-1441
55. Mendes P. Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. Trends Biochem Sci 22 (1997) 361-363
56. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28 (2005) 57-87
57. Mosharov E.V., Staal R.G.W., Bové J., Prou D., Hananiya A., Markov D., et al. α-Synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26 (2006) 9304-9311
58. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonucelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disord 19 (2004) 997-1005
59. Park S.S., Schulz E.M., and Lee D. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by α-synuclein. Eur J Neurosci 26 (2007) 3104-3112
60. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22 (2002) 3090-3099
61. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 (2002) 1007-1019
62. Pfeiffer T., Sanchez-Valdenebro I., Nuno J.C., Montero F., and Schuster S. METATOOL: for studying metabolic networks. Bioinformatics 15 (1999) 251-257
63. Piper R.C., and Luzio J.P. Ubiquitin-dependent sorting of integral membrane proteins for degradation in lysosomes. Curr Opin Cell Biol 19 (2007) 459-465
64. Qi Z., Miller G.W., and Voit E.O. Computational systems analysis of dopamine metabolism. PLoS ONE 2 (2008) e2444
65. Raichur A., Vali S., and Gorin F. Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease. Neuroscience 142 (2006) 859-870
66. Rubinsztein D.C. Autophagy induction rescues toxicity mediated by proteasome inhibition. Neuron 54 (2007) 854-856
67. Rubinsztein D.C., DiFiglia M., Heintz N., Nixon R.A., Qin Z., Ravikumar B., et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1 (2005) 11-22
68. Sakata E., Yamaguchi Y., Kurimoto E., Kikuchi J., Yokoyama S., Yamada S., et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep 4 (2003) 301-306
69. Savageau M.A. Biochemical systems analysis. I. Some mathematical properties of the rate law for the component enzymatic reactions. J Theor Biol 25 (1969) 365-369
70. Savageau M.A. Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. J Theor Biol 25 (1969) 370-379
71. Savageau M.A. Biochemical systems analysis. III. Dynamic solutions using a power-law approximation. J Theor Biol 26 (1970) 215-226
72. Schwarz R., Musch P., von Kamp A., Engels B., Schirmer H., Schuster S., et al. YANA-a software tool for analyzing flux modes, gene expression and enzyme activities. BMC Bioinform 6 (2005) 135
73. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp Neurol 179 (2003) 9-16
74. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
75. In: Siegel G.J., Albers R.W., Brady S.T., and Price D.L. (Eds). Basic neurochemistry: molecular, cellular and medical aspects (2006), Elsevier Academic Press, Burlington, MA
76. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., and Wolozin B. Aggregated and monomeric α-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem 278 (2003) 11753-11759
77. Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M.B.H. Selective increase of iron in substantia nigra zone compacta of parkinsonian brain. J Neurochem 56 (1991) 978-982
78. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
79. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci 95 (1998) 6469-6473
80. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., and Green L.A. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21 (2001) 9549-9560
81. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30 (2007) 244-250
82. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9 (2000) 2683-2689
83. Tan Z., Tu W., and Schreiber S.S. Downregulation of free ubiquitin: a novel mechanism of p53 stabilization and neuronal cell death. Mol Brain Res 91 (2001) 179-188
84. Thrower J.S., Hoffman L., Rechsteiner M., and Pickart C.M. Recognition of the polyubiqtuitin proteolytic signal. EMBO J 19 (2000) 94-102
85. Uhl G.R., Li S., Takahashi N., Itokawa K., Lin Z., Hazama M., et al. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J 14 (2000) 2459-2465
86. Voit E.O. Computational analysis of biochemical systems: a practical guide for biochemists and molecular biologists (2000), Cambridge University Press, New York
87. von Coelln R., Dawson V.L., and Dawson T.M. Parkin-associated Parkinson's disease. Cell Tissue Res 318 (2004) 175-184
88. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., and Rubinsztein D.C. α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278 (2003) 25009-25013
89. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., and Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246 (1989) 670-673
90. Xu Y., Stokes A.H., Roskoski Jr. R., and Vrana K.E. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neuro Res 54 (1998) 691-697
91. Zecca L., Tampellini D., Gerlach M., Riederer P., Fariello R.G., and Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 54 (2001) 414-418
92. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci 97 (2000) 13354-13359